Sarepta Therapeutics, Inc. (SRPT)
$16.51-5.33%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV41.4%–203.6%
- Market cap
- $1.7B
- Beta
- 0.20
- P/E (TTM)
- -11.69
- IV-%ile
- 7
- IV ATM
- 52.8%
- Short % float
- 24.08%
- Days to cover
- 8.6
- SI change
- -10.4%
- 1W
- -4.62%
- 1M
- -21.08%
- vs SPY 1W
- -4.48%
- vs SPY 1M
- -23.59%
Industry peers
FMP comparable companies · ranked by market cap
- ALNYSELLAlnylam Pharmaceuticals, Inc.$31.1BRECOVERYQ 28$232.68-1.41%
- IONSSELLIonis Pharmaceuticals, Inc.$7.5BCRISISQ 8$45.28-2.95%
- PTCTSELLPTC Therapeutics, Inc.$5.4BCRISISQ 18$64.70-4.77%
- DYNSELLDyne Therapeutics, Inc.$3.1BCRISISQ 3$16.64-4.14%
- NTLABUYIntellia Therapeutics, Inc.$1.8BRECOVERYQ 3$13.07-5.33%
- DSGNSELLDesign Therapeutics, Inc.$728MCRISISQ -14$11.65-10.36%
- WVESELLWave Life Sciences Ltd.$682MCRISISQ 7$3.46-4.27%
- SLDBSELLSolid Biosciences Inc.$676MCRISISQ -13$6.87-13.26%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on SRPT?
- LOPJLB’s latest quantitative signal on Sarepta Therapeutics, Inc. (SRPT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SRPT in?
- Sarepta Therapeutics, Inc. (SRPT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Sarepta Therapeutics, Inc. (SRPT) do?
- Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mut…